Zobrazeno 1 - 10
of 10
pro vyhledávání: '"A Bonilla-Navarrete"'
Autor:
Fabio Andrés Sinisterra Solís, Francisco Rubén Romero Castellanos, Emilly Alejandra Cortés Mancera, Ana L. Calderón Ávila, Sofía Denisse González Rueda, Juan Salvador Rosales García, Nora Estela Kerik Rotenberg, Dioselina Panamá Tristán Samaniego, Andrés Mauricio Bonilla Navarrete
Publikováno v:
Brain Sciences, Vol 14, Iss 9, p 930 (2024)
Parkinsonian syndromes are considered clinicopathological conditions that are challenging to diagnose. Molecular imaging with [18F]-FDOPA and [18F]-FDG contributes to a more accurate clinical diagnosis by evaluating presynaptic dopaminergic pathways
Externí odkaz:
https://doaj.org/article/82318381832b4ad2aa21b82fb2029f1c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Cacho-Díaz, Bernardo, González-González, Ethan, Mauricio Bonilla-Navarrete, Andrés, Texcocano-Becerra, Julia, Oñate-Ocaña, Luis F.
Publikováno v:
In Journal of Clinical Neuroscience May 2023 111:39-45
Autor:
Sinisterra Solís, Fabio Andrés, Romero Castellanos, Francisco Rubén, Cortés Mancera, Emilly Alejandra, Calderón Ávila, Ana L., González Rueda, Sofía Denisse, Rosales García, Juan Salvador, Kerik Rotenberg, Nora Estela, Tristán Samaniego, Dioselina Panamá, Bonilla Navarrete, Andrés Mauricio
Publikováno v:
Brain Sciences (2076-3425); Sep2024, Vol. 14 Issue 9, p930, 16p
Autor:
Bernardo Cacho-Díaz, Ethan González-González, Andrés Mauricio Bonilla-Navarrete, Julia Texcocano-Becerra, Luis F. Oñate-Ocaña
Publikováno v:
Journal of Clinical Neuroscience. 111:39-45
Autor:
Y Garcilazo-Reyes, N Zapata-Canto, B Cacho-Díaz, O Navarro-Fernández, R Espinoza-Zamora, A Bonilla-Navarrete, A Avilés-Salas
Publikováno v:
Neuro-Oncology. 24:ii75-ii75
Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive myeloid hematological malignancy. Skin lesions, bone marrow, lymph nodes or visceral organs can be involved. 30% of patients will have infiltration to the nervous sy
Publikováno v:
1. Barrera-Vargas A, Quintanar-Martínez M, Merayo-Chalico J, Alcocer-Varela J, Gómez-Martín D. Risk factors for systemic lupus erythematosus flares in patients with end-stage renal disease: a case–control study. Rheumatology. 21 de septiembre de 2015;kev349.
2. Mattos P, Santiago MB. Disease activity in systemic lupus erythematosus patients with end-stage renal disease: systematic review of the literature. Clin Rheumatol. junio de 2012;31(6):897-905.
3. Irene Carrión-Barberà, Tarek Carlos Salman-Monte, F. Vílchez-Oya, Jordi Monfort, Neuropsychiatric involvement in systemic lupus erythematosus: A review, Autoimmunity Reviews, Volume 20, Issue 4, 2021, 102780.
Miyawaki, Y., Shimizu, S., Ogawa, Y. et al. Association of glucocorticoid doses and emotional health in lupus low disease activity state (LLDAS): a cross-sectional study. Arthritis Res Ther 23, 79 (2021).
5. Damrongpipatkul, U., Oranratanachai, K., Kasitanon, N., Wuttiplakorn, S., & Louthrenoo, W. (2017). Clinical features, outcome, and associated factors for posterior reversible encephalopathy in Thai patients with systemic lupus erythematosus: a case-control study. Clinical Rheumatology, 37(3), 691–702. doi:10.1007/s10067-017-3892-2
6. Cardiel MH, Soriano ER, Bonfá ESD de O, Alarcón GS, Izcovich A, Amigo Castañeda MC, et al. Therapeutic Guidelines for Latin American Lupus Patients: Methodology. JCR J Clin Rheumatol. diciembre de 2017;1.
Gómez-Puerta JA, Cervera R. Lupus eritematoso sistémico. Med Lab. 2008;14(5):211–23.
8. Lee PT, Fang HC, Chen CL, Chiou YH, Chou KJ, Chung HM. Poor prognosis of end-stage renal disease in systemic lupus erythematosus: a cohort of Chinese patients. Lupus. 2003:12 (11):827–832
9. Goo YS, Park HC, Choi HY, Kim BS, Park YB, Lee SK et al. The evolution of lupus activity among patients with endstage renal disease secondary to lupus nephritis. Yonsei Med J. 2004:45(2):199–206
11. Siu YP, Leung KT, Tong MK, Kwan TH, Mok CC. Clinical outcomes of systemic lupus erythematosus patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2005:20(12):2797–2802
12. Inda-Filho A, Neugarten J, Putterman C, Broder A. Improving Outcomes in Patients with Lupus and End-Stage Renal Disease. Semin Dial. septiembre de 2013;26(5):590-6.
13. Maroz N, Segal MS. Lupus nephritis and end-stage kidney disease. Am J Med Sci. 2013;346(4):319–323.
14. Moon SJ, Park HS, Kwok SK, Ju JH, Kim HY, Park SH. Predictors of end-stage renal disease and recurrence of lupus activity after initiation of dialysis in patients with lupus nephritis. Clin Exp Rheumatol. 2013;31:31–39.
15. Kang SH, Chung BH, Choi SR, Lee JY, Park HS, Sun IO et al. Comparison of clinical outcomes by different renal replacement therapy in patients with end-stage renal disease secondary to lupus nephritis. Korean J Intern Med. 2011:26(1):60–67
16. 59ª Asamblea General. Declaración de Helsinki. Seúl, Corea, octubre de 2008.
17. Ministerio de Salúd de la República De Colombia. De los aspectos éticos de la investigación en séres humanos. Resolución Número 8430. 1993:1:2-5.
18. Magro-Checa C, Zirkzee EJ, Huizinga TW, Steup-Beekman GM. Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. Drugs. marzo de 2016;76(4):459-83.
19. Zhang Y, Han H, Chu L. Neuropsychiatric Lupus Erythematosus: Future Directions and Challenges; a Systematic Review and Survey. Clinics. 2020;75:e1515.
20. Nayak-Rao, S, and M P Shenoy. “Stroke in Patients with Chronic Kidney Disease…: How do we Approach and Manage it?.” Indian journal of nephrology vol. 27,3 (2017): 167-171.
21. Almannai M, Al Mahmoud RA, Mekki M, El-Hattab AW. Metabolic Seizures. Front Neurol. 2021;12:985.
22. Guenzani, D., Buoli, M., Carnevali, G. S., Serati, M., Messa, P., & Vettoretti, S. (2018). Is there an association between severity of illness and psychiatric symptoms in patients with chronic renal failure? Psychology, Health & Medicine, 23(8), 970–979.
23. Kivity, S., Agmon-Levin, N., Zandman-Goddard, G. et al. Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Med 13, 43 (2015).
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
2. Mattos P, Santiago MB. Disease activity in systemic lupus erythematosus patients with end-stage renal disease: systematic review of the literature. Clin Rheumatol. junio de 2012;31(6):897-905.
3. Irene Carrión-Barberà, Tarek Carlos Salman-Monte, F. Vílchez-Oya, Jordi Monfort, Neuropsychiatric involvement in systemic lupus erythematosus: A review, Autoimmunity Reviews, Volume 20, Issue 4, 2021, 102780.
Miyawaki, Y., Shimizu, S., Ogawa, Y. et al. Association of glucocorticoid doses and emotional health in lupus low disease activity state (LLDAS): a cross-sectional study. Arthritis Res Ther 23, 79 (2021).
5. Damrongpipatkul, U., Oranratanachai, K., Kasitanon, N., Wuttiplakorn, S., & Louthrenoo, W. (2017). Clinical features, outcome, and associated factors for posterior reversible encephalopathy in Thai patients with systemic lupus erythematosus: a case-control study. Clinical Rheumatology, 37(3), 691–702. doi:10.1007/s10067-017-3892-2
6. Cardiel MH, Soriano ER, Bonfá ESD de O, Alarcón GS, Izcovich A, Amigo Castañeda MC, et al. Therapeutic Guidelines for Latin American Lupus Patients: Methodology. JCR J Clin Rheumatol. diciembre de 2017;1.
Gómez-Puerta JA, Cervera R. Lupus eritematoso sistémico. Med Lab. 2008;14(5):211–23.
8. Lee PT, Fang HC, Chen CL, Chiou YH, Chou KJ, Chung HM. Poor prognosis of end-stage renal disease in systemic lupus erythematosus: a cohort of Chinese patients. Lupus. 2003:12 (11):827–832
9. Goo YS, Park HC, Choi HY, Kim BS, Park YB, Lee SK et al. The evolution of lupus activity among patients with endstage renal disease secondary to lupus nephritis. Yonsei Med J. 2004:45(2):199–206
11. Siu YP, Leung KT, Tong MK, Kwan TH, Mok CC. Clinical outcomes of systemic lupus erythematosus patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2005:20(12):2797–2802
12. Inda-Filho A, Neugarten J, Putterman C, Broder A. Improving Outcomes in Patients with Lupus and End-Stage Renal Disease. Semin Dial. septiembre de 2013;26(5):590-6.
13. Maroz N, Segal MS. Lupus nephritis and end-stage kidney disease. Am J Med Sci. 2013;346(4):319–323.
14. Moon SJ, Park HS, Kwok SK, Ju JH, Kim HY, Park SH. Predictors of end-stage renal disease and recurrence of lupus activity after initiation of dialysis in patients with lupus nephritis. Clin Exp Rheumatol. 2013;31:31–39.
15. Kang SH, Chung BH, Choi SR, Lee JY, Park HS, Sun IO et al. Comparison of clinical outcomes by different renal replacement therapy in patients with end-stage renal disease secondary to lupus nephritis. Korean J Intern Med. 2011:26(1):60–67
16. 59ª Asamblea General. Declaración de Helsinki. Seúl, Corea, octubre de 2008.
17. Ministerio de Salúd de la República De Colombia. De los aspectos éticos de la investigación en séres humanos. Resolución Número 8430. 1993:1:2-5.
18. Magro-Checa C, Zirkzee EJ, Huizinga TW, Steup-Beekman GM. Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. Drugs. marzo de 2016;76(4):459-83.
19. Zhang Y, Han H, Chu L. Neuropsychiatric Lupus Erythematosus: Future Directions and Challenges; a Systematic Review and Survey. Clinics. 2020;75:e1515.
20. Nayak-Rao, S, and M P Shenoy. “Stroke in Patients with Chronic Kidney Disease…: How do we Approach and Manage it?.” Indian journal of nephrology vol. 27,3 (2017): 167-171.
21. Almannai M, Al Mahmoud RA, Mekki M, El-Hattab AW. Metabolic Seizures. Front Neurol. 2021;12:985.
22. Guenzani, D., Buoli, M., Carnevali, G. S., Serati, M., Messa, P., & Vettoretti, S. (2018). Is there an association between severity of illness and psychiatric symptoms in patients with chronic renal failure? Psychology, Health & Medicine, 23(8), 970–979.
23. Kivity, S., Agmon-Levin, N., Zandman-Goddard, G. et al. Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Med 13, 43 (2015).
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
El lupus eritematoso sistémico (LES) es una enfermedad autoinmune y crónica de causa aún desconocida (1). El compromiso neuropsiquiátrico es una complicación relativamente frecuente durante la actividad lúpica y se caracteriza por síndromes ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2518d0b94328e5fbc5a796e1a845bbb7
Autor:
Armando Meza, Oscar Lopez, Yara Tovar, Zuber D. Mulla, Fernando Chedebeau, Aracely Bonilla-Navarrete, Nina E. Flavin
Publikováno v:
Southern Medical Journal. 102:805-809
Background Lack of health insurance can adversely affect access to medical care which leads to poor disease outcome. Few studies examine the effects of no insurance on the development of diabetes complications. The objective of this study was to dete
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.